Imaging study for advanced cancers
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial is testing a new imaging method to see if it can help find cancer that has spread in people with certain advanced cancers like bladder cancer, breast cancer, or lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with one of these cancers that has spread: bladder cancer, HR+ and HER2- breast cancer, triple-negative breast cancer, or non-small cell lung cancer.
- If you are a woman who could become pregnant, you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
This early-phase study uses a special imaging agent called RYZ512 to see how it works in people with advanced clear cell kidney cancer that has spread. Participants will receive RYZ512 and have scans; you may qualify if you can pause certain medications temporarily.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
This trial tests a new radioactive imaging agent (111In-XYIMSR-01) to see how well it finds clear cell kidney cancer that has spread. It involves a special SPECT/CT scan and may help doctors better see where the cancer is.
Hear when a new Metastatic Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.